title: Innovations in vaccine development: can regulatory authorities keep up?
abstract: Vaccine Production Summit   San Francisco, CA, USA, 4-6 June 2012   IBC's 3rd Vaccine Production Summit featured 28 presentations discussing regulatory challenges in vaccine development, including the use of adjuvants, vaccine manufacturing and technology transfer, process development for vaccines and the role of quality by design, how to address vaccine stability, and how vaccine development timelines can be improved. The conference was run in parallel with the single-use applications for Biopharmaceutical Manufacturing conference. Approximately 250 attendees from large pharmaceutical companies, large and small biotech companies, vendors and a more limited number from academia were allowed to access sessions of either conference, including one shared session. This article summarizes the recurring themes across various presentations.
authors.affiliation: Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA. manon.cox@proteinsciences.com
authors.forename: Manon M J
authors.initials: MM
authors.lastname: Cox
authors.forename: Annelies
authors.initials: A
authors.lastname: Onraedt
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000592:standards; D000818:Animals; D017277:Drug Approval / Q000379:methods*; D006801:Humans; D062069:Inventions / Q000592:standards / Q000639:trends; D013678:Technology, Pharmaceutical / Q000592:standards / Q000639:trends; D014611:Vaccination / Q000379:methods / Q000592:standards; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology* / Q000592:standards
chemical_list: D000276:Adjuvants, Immunologic; D014612:Vaccines